CredibleX | $55,000,000 | (Dec 18, 2024)
T-robotics | $5,400,000 | (Dec 18, 2024)
Chargezoom | $11,500,000 | (Dec 18, 2024)
Cullgen Inc.
United States
- San Diego, California
- 09/05/2023
- Unknown
- $40,000,000
Cullgen is a biopharmaceutical company that has developed protein degradation technology that utilizes the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Our technology, which we call uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) has the potential to address a broad range of intracellular disease targets, including those representing the up to 80% of proteins that cannot be addressed by existing small molecule therapies, commonly referred to as undruggable targets. In addition to using our uSMITE™ platform to build our own pipeline of protein degradation product candidates, we are also developing a portfolio of novel E3 ligands. You can learn more information about Cullgen on our website: www.Cullgen.com
- Industry Biotechnology Research
- Website https://www.cullgen.com/
- LinkedIn https://www.linkedin.com/company/cullgen/
BILT Incorporated | $21,000,000 | (Dec 18, 2024)
Fluid Biomed Inc. | $27,000,000 | (Dec 18, 2024)
FastWave Medical | $19,000,000 | (Dec 18, 2024)
Prequel.dev | $3,300,000 | (Dec 18, 2024)
Mili | $2,000,000 | (Dec 18, 2024)
Stand | $30,000,000 | (Dec 18, 2024)
Anatomy Financial | $19,000,000 | (Dec 18, 2024)
pagent.ai | Undisclosed Amount | (Dec 18, 2024)
Slip Robotics | $28,000,000 | (Dec 18, 2024)
Twill | $1,400,000 | (Dec 18, 2024)